Wang IK, Yen TH, Guo YC, et al. - Researchers used the Taiwan Stroke Registry data to compare the effectiveness of aspirin, clopidogrel and dual antiplatelet therapy with combination of both aspirin and clopidogrel on the secondary prevention of stroke by estimated glomerular filtration rate (eGFR) levels measured at the time of admission for ischaemic stroke. At admission, the re-stroke incidence and 1-year mortality were stratified by eGFR levels: ≥ 90, 60–89 and < 60 ml/min/1.73 m² or on dialysis. Participants in the study were 39,174 acute ischaemic stroke patients. For ischaemic stroke patients with or without renal dysfunction receiving antiplatelet agents with aspirin, clopidogrel or dual agents combined with aspirin and clopidogrel, there was no difference in the risks of recurrent stroke and 1-year mortality, irrespective of their renal dysfunction status.